Phosphodiesterase 4 and tolerance to 2 -adrenoceptor agonists in asthma

Author： Giembycz M.A.  

Publisher： Elsevier

ISSN： 0165-6147

Source： Trends in Pharmacological Sciences, Vol.17, Iss.9, 1996-09, pp. : 331-336

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

-Adrenoceptor agonists and asthma-100 years of development

By Waldeck B.  

European Journal of Pharmacology, Vol. 445, Iss. 1, 2002-06 ,pp. : 1-12

Elsevier

Access to resources Recommend Favorite

Long-Acting 2-Adrenoceptor Agonists and Exercise-Induced Asthma: Lessons to Guide Us in the Future

By Anderson Sandra D.   Brannan John D.  

Pediatric Drugs, Vol. 6, Iss. 3, 2004-01 ,pp. : 161-175

Adis International

Access to resources Recommend Favorite

Ultra-Long-Acting β2-Adrenoceptor Agonists: An Emerging Therapeutic Option for Asthma and COPD?

By Maria Gabriella Matera  

Drugs, Vol. 67, Iss. 4, 2007-01 ,pp. : 503-515

Adis International

Access to resources Recommend Favorite

Differential cross-tolerance between analgesia produced by 2 -adrenoceptor agonists and receptor subtype selective opioid treatments

By Paul D.   Tran J.G.  

European Journal of Pharmacology, Vol. 272, Iss. 1, 1995-01 ,pp. : 111-114

Elsevier

Access to resources Recommend Favorite

Phosphodiesterase 4 inhibitors for the treatment of asthma

By Karlsson J-A.   Aldous D.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 9, 1997-09 ,pp. : 989-1003

Informa Healthcare

Access to resources Recommend Favorite